GCM
CATX icon

Graham Capital Management’s Perspective Therapeutics CATX Stock Holding History

Graham Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-80,193
Closed -$221K – 1198
2025
Q4 		$221K Buy
80,193
+34,836
+77% +$99.4K 0.01% 1003
2025
Q3 		$156K Buy
+45,357
New +$165K ﹤0.01% 1111

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Graham Capital Management's CATX Position: Q1 2026 in Review

Graham Capital Management sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 80,193 shares — an estimated $221K sold.

Graham Capital Management first reported a position in CATX in Q3 2025 and held it in 2 quarters. The position peaked at $221K in Q4 2025. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Graham Capital Management reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 80,193 Perspective Therapeutics shares in Q1 2026, an estimated $221K.
  • Graham Capital Management first reported a position in Perspective Therapeutics in Q3 2025 and held it in 2 quarters.
  • Graham Capital Management's Perspective Therapeutics position peaked at $221K in Q4 2025.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.